Nuvalent (NASDAQ:NUVL) Sets New 1-Year High – What’s Next?

Nuvalent, Inc. (NASDAQ:NUVL) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $123.83 and last traded at $123.77, with a volume of 1077919 shares. The stock had previously closed at $123.72.

Analyst Ratings Changes

A number of research analysts recently weighed in on NUVL shares. Robert W. Baird set a $122.85 price target on shares of Nuvalent in a research report on Tuesday, June 9th. Guggenheim lowered shares of Nuvalent from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $151.00 to $124.00 in a research note on Wednesday, June 10th. TD Cowen cut shares of Nuvalent from a “buy” rating to a “hold” rating and set a $124.00 target price on the stock. in a research report on Tuesday, June 9th. Wells Fargo & Company restated an “equal weight” rating and issued a $124.00 target price (up from $116.00) on shares of Nuvalent in a research note on Tuesday, June 9th. Finally, HC Wainwright downgraded shares of Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 target price for the company. in a research report on Tuesday, June 9th. Four equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $127.73.

Nuvalent Price Performance

The firm has a market capitalization of $9.78 billion, a PE ratio of -20.43 and a beta of 1.14. The company’s fifty day simple moving average is $111.23 and its 200 day simple moving average is $105.74.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same period in the previous year, the firm posted ($1.18) EPS. On average, analysts anticipate that Nuvalent, Inc. will post -5.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Nuvalent

In other Nuvalent news, insider Deborah Ann Miller sold 5,500 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $107.84, for a total transaction of $593,120.00. Following the sale, the insider owned 59,634 shares in the company, valued at $6,430,930.56. This represents a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Alexandra Balcom sold 11,430 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $123.58, for a total value of $1,412,519.40. Following the completion of the transaction, the chief financial officer directly owned 85,533 shares of the company’s stock, valued at $10,570,168.14. The trade was a 11.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 123,860 shares of company stock valued at $13,097,576 in the last 90 days. 5.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its holdings in shares of Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Nuvalent by 141.3% in the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after acquiring an additional 195 shares during the period. NBC Securities Inc. purchased a new position in Nuvalent during the fourth quarter valued at approximately $125,000. KBC Group NV grew its stake in Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after acquiring an additional 297 shares in the last quarter. Finally, US Bancorp DE increased its holdings in Nuvalent by 10.0% during the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company’s stock worth $179,000 after acquiring an additional 188 shares during the period. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.